Shree Ganesh Rem (540737)
Fast GrowerScore breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹796.3 |
| Market Cap | ₹1,032.03 Cr |
| P/E Ratio | 36.31 |
| ROCE | 19.21% |
| ROE | 13.59% |
| Dividend Yield | 0% |
| Profit Growth | -42.91% |
| Debt/Equity | — |
| Sales Growth | -21.96% |
| 52-Week Range | ₹381.1 — ₹796.3 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹106.93 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
When I look at Shree Ganesh Rem, I see a business whose numbers are moving in the wrong direction. Sales are down 21.96%, profit is down 42.91%, and the latest quarter is small: ₹21 Cr sales and ₹3 Cr net profit. At the current price of ₹796.30, the market capitalisation is ₹1,032 Cr. That means I am being asked to pay 36.31 times earnings and 7.45 times book value. Benjamin Graham taught me that price is what you pay and value is what you get. Here, I am paying a rich multiple for a shrinking franchise. ROE of 13.59% and ROCE of 19.21% look respectable at first, but they are trailing numbers from a business that is already contracting. The Piotroski F-Score of 3/9 and the FairStock Score of 0/100 signal weak financial health, and with zero dividend yield, there is no income cushion if the market reprices the stock. The share is trading at the top of its 52-week range of ₹381.10 to ₹796.30, so Mr. Market is already optimistic. I do not buy hope at 36 times earnings. I need growth, predictability, and a margin of safety. This stock has none of the three. I would leave it to speculators.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer